2012-09-18 13:56:09 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Guangzhou Pharmaceutical Company Limited and produced a Rating Update Report, rating the company's attractiveness to long-term investors.

Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering Guangzhou Pharmaceutical Company Limited (874). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Guangzhou Pharmaceutical Company Limited investor.

Report Summary: Guangzhou Pharmaceutical Company Limited is a below average quality company with a neutral outlook. Guangzhou Pharmaceutical Company Limited has medium business growth and is run by passable management. The trend in Guangzhou Pharmaceutical Company Limited fair value exchange rate against its closest rated-competitor, Wuyi Intl. Pharmaceutical Co., Ltd., has been appreciating over the past 2 weeks. When compared to its closest competitor, Guangzhou Pharmaceutical Company Limited shows less overvaluation and is equally likely to underperform the market.

The 3-page

report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Guangzhou Pharmaceutical Company Limited for long-term investors.

The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
www.sadifanalytics.com/stockmarks/company-ru-45-874

About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.